Skip to main content

KIF5A KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

Be the first to review this product! Submit a review

Images

Western blot - Human KIF5A knockout U-87 MG cell line (AB306717), expandable thumbnail
  • Western blot - Human KIF5A knockout U-87 MG cell line (AB306717), expandable thumbnail
  • Next Generation Sequencing - Human KIF5A knockout U-87 MG cell line (AB306717), expandable thumbnail
  • Next Generation Sequencing - Human KIF5A knockout U-87 MG cell line (AB306717), expandable thumbnail

Key facts

Cell type
U-87 MG
Species or organism
Human
Tissue
Brain
Form
Liquid
Knockout validation
Next Generation Sequencing

What's included?

1000000 Cells/vial
Components
Human KIF5A knockout U-87 MG cell line kit component
1 x 1000000 Cells/vial

KIF5A KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

Key facts

Cell type
U-87 MG
Form
Liquid
Disease
Glioblastoma
Concentration
Loading...

Properties

Gene name
KIF5A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing

Cell culture

Viability
> 60%
Adherent/suspension
Adherent
Gender
Male

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
EMEM + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

4 product images

  • Western blot - Human KIF5A knockout U-87 MG cell line (ab306717), expandable thumbnail

    Western blot - Human KIF5A knockout U-87 MG cell line (ab306717)

    All lanes: Western blot - Anti-KIF5A antibody (Anti-KIF5A antibody ab154378) at 1/1000 dilution

    Lane 1: Wild-type U-87 MG ab278079 at 20 µg

    Lane 2: Western blot - Human KIF5A knockout U-87 MG cell line (ab306717) at 20 µg

    Lane 3: SK-N-FI at 20 µg

    Lane 4: HEK-293T at 20 µg

    Secondary

    All lanes: Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

    Performed under reducing conditions.

    Predicted band size: 117 kDa

    Observed band size: 135 kDa

  • Western blot - Human KIF5A knockout U-87 MG cell line (ab306717), expandable thumbnail

    Western blot - Human KIF5A knockout U-87 MG cell line (ab306717)

    All lanes: Western blot - Anti-KIF5A antibody (Anti-KIF5A antibody ab5628) at 1/1000 dilution

    Lane 1: Wild-type U-87 MG ab278079 at 20 µg

    Lane 2: Western blot - Human KIF5A knockout U-87 MG cell line (ab306717) at 20 µg

    Lane 3: SK-N-FI at 20 µg

    Lane 4: HEK-293T at 20 µg

    Secondary

    All lanes: Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution

    Performed under reducing conditions.

    Predicted band size: 117 kDa

    Observed band size: 135 kDa

  • Next Generation Sequencing - Human KIF5A knockout U-87 MG cell line (ab306717), expandable thumbnail

    Next Generation Sequencing - Human KIF5A knockout U-87 MG cell line (ab306717)

    53 bp deletion (allele 1) and 52 bp deletion (allele 2) in exon 10, CCDS8945.1

  • Next Generation Sequencing - Human KIF5A knockout U-87 MG cell line (ab306717), expandable thumbnail

    Next Generation Sequencing - Human KIF5A knockout U-87 MG cell line (ab306717)

    7 bp deletion in exon 4, CCDS773.1

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com